Palbonix (Palbociclib) indicate for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:<\/p>\n
<\/p>\n
Due to its mechanism of action, Palbociclib<\/a> inhibits cell growth and suppresses DNA replication in retinoblastoma tumor suppressor gene (RB) proficient cancer cells. As expected, these RB cells present a significant increase in the proportion of cells in G1 state and the presence of Palbociclib produces effective dephosphorylation of RB, reduce proliferation and induce senescence causing cell-cycle arrest.<\/p>\n The potential for Palbociclib to reduce cellular proliferation of estrogen receptor-positive breast cancer cell lines through the inhibition of the cell-cycle progression from G1 to S phase. In this study, it was demonstrated that the sensitivity of the cells significantly increased with the expression of RB1<\/em>\u00a0and\u00a0CCND1<\/em>\u00a0and low expression of\u00a0CDKN2A<\/em>. As well, Palbociclib, combined with antiestrogens, enhanced in vivo<\/em> antitumor activity in estrogen receptor-positive breast cancer mouse models.<\/p>\n In clinical trials, Palbonix , in combination with letrozole, was shown to significantly increase the progression-free survival (PFS) in patients with metastatic breast cancer without prior endocrine treatment. In the results, the PFS increased from 4.5 to 9.5 months with an overall response rate (ORR) of 24.6%.<\/p>\n <\/p>\n Palbonix is a cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor1<\/a><\/sup>\u00a0that acts by binding to the ATP pocket with an IC50 in the range of 9-15 nmol\/L. It is important to consider that it presents low to absent activity against other kinases.<\/p>\n The CDK4\/6 kinase is involved, with coregulatory partner cyclin D, in the G1-S transition. Hence, inhibition of this step prevents cell cycle progression in cells in whose this pathway is functioning. This step includes the pathways of the phosphorylation of retinoblastoma protein and the E2F family of transcription factors.<\/p>\n <\/p>\n The most common side effects of Palbociclib are:<\/p>\n <\/p>\n Palbonix 125 (Palbociclib)\u00a0125mg\u00a0capsules<\/a> are taken orally with food in combination with an aromatase inhibitor or fulvestrant.<\/p>\n <\/p>\n <\/p>\n Q. Is Palbonix (Palbociclib) available to supply worldwide?<\/strong><\/p>\n Yes! We can supply Palbonix (Palbociclib) worldwide. According to WTO rules and regulations, we can supply our prescription medicine in most of the country for patient\u2019s personal use.<\/p>\n Q. What\u2019s the Palbonix (Palbociclib) minimum order quantity?<\/strong><\/p>\n Minimum quantity order of Palbonix (Palbociclib) depends on client\/ patients demand. We\u2019ll notify it after price inquiring.<\/p>\n Q. What\u2019s the Palbonix (Palbociclib) price\/ cost in\u00a0 Russia\/ USA\/ UK\/ India\/ China\/ Egypt\/ other countries?<\/strong><\/p>\n Palbonix (Palbociclib) price\/ cost will be provided after getting valid order from clients\/ patients. We\u2019ll notify it after price inquiring.<\/p>\n Q. How I can order Palbonix (Palbociclib)?<\/strong><\/p>\n To order this Palbonix (Palbociclib), please inquiry the price first with proper information and then add to cart.<\/p>\n Q. How I\u2019ll be ensured that I\u2019m getting the original Palbonix (Palbociclib)?<\/strong><\/p>\n First of all, we\u2019re licensed online pharmacy service provider. We supply most kind of generic prescription medicine globally. We\u2019ve dealings directly with manufacturing pharma company or with their authorized agent. Therefore, here is no doubt to get original Palbonix (Palbociclib) by us. And also, you can check the security code that provided by manufacturing company whether it\u2019s genuine or not. If you feel any issue or doubt, please inform us immediately.<\/p>\n For any inquiries please contact us<\/a><\/strong><\/p>\nMechanism of Action<\/h4>\n
Palbonix side effects<\/h4>\n
\n
Palbociclib Dosage<\/h4>\n
\n
FAQ about Palbonix (Palbociclib):<\/strong><\/h3>\n